fatty liver in patients with polycystic ovary syndrome,(Only fatty liver is considered). Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Patients (women of reproductive age suffering from non-alcoholic fatty liver with polycystic ovary syndrome) receiving 500 mg curcumin capsules (prepared from the e
It is given to patients at a dose of 500 mg twice a day for three months.
Sponsors
The University of Tarbiat Modares
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Women of reproductive age from 18 to 45 years old Women with polycystic ovary syndrome and non-alcoholic fatty liver disease Having two of the three Rotterdam criteria including: having polycystic ovary ultrasound view, having serum hyperandrogenism with/without clinical symptoms related to hyperandrogenism such as acne, hirsutism, acanthosis nigricans, etc., having disordered ovulation and irregular menstrual cycle. Being able to speak and write in Farsi
Exclusion criteria
Exclusion criteria: Pregnancy Breastfeeding Using hormonal methods to prevent pregnancy Having any other diagnosed disease Being allergic to turmeric History of advanced chronic liver disease Use of tobacco and alcohol Drug addiction Adrenal hyperplasia that has symptoms similar to polycystic ovary syndrome Renal failure or any other active digestive disorder Non-metabolic chronic diseases Thyroid disease Hyperprolactinemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver ultrasound appearance (grade change). Timepoint: Before the intervention and 48 hours after the end of the intervention. Method of measurement: There is no need to fast, and as soon as possible, the patient will be referred to a sonographer to carry out diagnostic and examination procedures according to specific criteria for checking fatty liver.;Body mass index (BMI). Timepoint: Before the intervention and 48 hours after the end of the intervention. Method of measurement: Measuring height with a centimeter tape and measuring weight with a digital scale and then entering the obtained values into the formula of weight in kilograms divided by the square of height in meters to calculate the body mass index.;The level of low-density lipoprotein (LDL). Timepoint: before the intervention and 48 hours after the intervention. Method of measurement: laboratory test.;The level of high-density lipoprotein (HDL). Timepoint: before the intervention and 48 hours after the intervention. Method of measurement: laboratory test.;The level of triglyceride (TG). Timepoint: before the intervention and 48 hours after the intervention. Method of measurement: laboratory test.;The level of cholesterol. Timepoint: before the intervention and 48 hours after the intervention. Method of measurement: laboratory test.;The level of alanine aminotransferase (ALT). Timepoint: before the intervention and 48 hours after the intervention. Method of measurement: laboratory test.;The level aspartate aminotransferase (AST). Timepoint: Before the intervention and 48 hours after the intervention. Method of measurement: laboratory test.;The level of alkaline phosphatase (ALP). Timepoint: Before the intervention and 48 hours after the intervention. Method of measurement: laboratory test. | — |
Secondary
| Measure | Time frame |
|---|---|
| The level of anxiety. Timepoint: Before the intervention and after the intervention. Method of measurement: With the history of taking and filling the DASS questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNajmeh Tehranian
The University of Tarbiat Modares
Outcome results
None listed